Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | VCP | P55072 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11290393 | 0.98 | TSHR (0.59) | TSHRLMNAALDH1A1ACHETDP1 | |
| Hydrochloric Acid SCHEMBL11290386 | 0.98 | TSHR (0.59) | TSHRLMNAALDH1A1ACHETDP1 | |
| SCHEMBL28239092 | 0.80 | TSHR (0.61) | TSHRLMNAALDH1A1ACHETDP1 | |
| Hydrochloric Acid SCHEMBL11567135 | 0.78 | TSHR (0.59) | TSHRLMNAALDH1A1ACHETDP1 | |
| Dinitrophenylene SCHEMBL36632 | 0.78 | TSHR (1.00) | TSHRLMNAALDH1A1ACHETDP1 | |
| Dinitrophenylene SCHEMBL29291896 | 0.78 | TSHR (1.00) | TSHRLMNAALDH1A1ACHETDP1 | |
| Perchlorate SCHEMBL5574429 | 0.76 | TSHR (0.55) | TSHRLMNAALDH1A1ACHETDP1 | |
| Dinitrophenylene SCHEMBL9733868 | 0.75 | TSHR (0.94) | TSHRLMNAALDH1A1ACHETDP1 | |
| Dinitrophenylene SCHEMBL11661349 | 0.75 | TSHR (0.94) | TSHRLMNAALDH1A1ACHETDP1 | |
| Dinitrophenylene SCHEMBL2997371 | 0.75 | TSHR (0.94) | TSHRLMNAALDH1A1ACHETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655203-B2 | Nitration | ETH ZURICH (CH) | 2023-05-23 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20180057465-A1 | Inhibitors of Necroptosis | CATALYST THERAPEUTICS PTY LTD (AU) | 2018-03-01 | — | — | US | disclosed |
| US-20170247352-A1 | METHOD FOR PREPARING ALECTINIB | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| US-9573932-B2 | Synthesis of intermediates in the preparation of ALK inhibitor | XU YONG (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160257667-A1 | SYNTHESIS OF INTERMEDIATES IN THE PREPARATION OF ALK INHIBITOR | XU YONG (US) | 2016-09-08 | — | — | US | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| EP-1901748-B1 | ANGIOGENESIS INHIBITORS | ONCALIS AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| EP-1765351-B9 | PROTEIN KINASE INHIBITORS | ONCALIS AG (CH) | 2010-03-24 | — | — | EP | disclosed |
| EP-1765351-B1 | PROTEIN KINASE INHIBITORS | ONCALIS AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008121602-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257667-A1 | SYNTHESIS OF INTERMEDIATES IN THE PREPARATION OF ALK INHIBITOR | ALK, ACVR1B, ETV6 | TSHR 3480/4885LMNA 1093/4885ALDH1A1 439/4885 |
| US-20150038534-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | TSHR 1016/4885LMNA 26/4885ALDH1A1 1152/4885 |
| US-20170247352-A1 | METHOD FOR PREPARING ALECTINIB | ADH1C, ADH1A, ALK | TSHR 2007/4885LMNA 376/4885ALDH1A1 166/4885 |
| US-20130059883-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | TSHR 1016/4885LMNA 26/4885ALDH1A1 1152/4885 |
| US-20180057465-A1 | Inhibitors of Necroptosis | RIPK3, RIPK1, AIFM1 | TSHR 4108/4885LMNA 1012/4885ALDH1A1 4651/4885 |
| US-11655203-B2 | Nitration | NOS1, NOS2, NOS3 | TSHR 2432/4885LMNA 4595/4885ALDH1A1 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.